Question: A 71-year-old man with chronic hepatitis B-related liver cirrhosis and hepatocellular carcinoma was brought to the emergency department because he had experienced progressive abdominal distension for 1 week. The hepatoma had recently progressed with portal vein invasion, and he had received sorafenib therapy (800 mg/d) for 4 weeks before this presentation. Dull abdominal discomfort occurred 2 weeks after the molecular target therapy, and this was considered to be a drug-related adverse event.